RT Journal Article
SR Electronic
T1 Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in pancreatic cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.30.24311246
DO 10.1101/2024.07.30.24311246
A1 Li, Xutai
A1 Zhang, Pengwu
A1 Zhang, Hui
A1 Sun, Chen
A1 Ge, Zhenjian
A1 Chen, Wenkang
A1 Li, Yingqi
A1 Lin, Shengjie
A1 Wang, Wuping
A1 Chen, Siwei
A1 Wu, Yutong
A1 Zhou, Huimei
A1 Li, Wei
A1 Feng, Fei
A1 Lin, Zewei
A1 Lai, Yongqing
YR 2024
UL http://medrxiv.org/content/early/2024/09/10/2024.07.30.24311246.abstract
AB Background Pancreatic cancer is a serious threat to human health. Enhanced CT is widely used in the diagnosis of pancreatic cancer. However, false-positive results of enhanced CT will bring unnecessary mental pain, expensive examination costs, physical injuries, and even adverse consequences such as organ removal and loss of function; while false-negative results of enhanced CT bring delayed treatment, and patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival period. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive and false-negative rates of enhanced CT in pancreatic tumors. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in pancreatic cancer.Patients and methods 62 subjects (malignant group, n=37; benign group, n=25) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.Results YiDiXie™-SS had a sensitivity of 100% (95% CI: 88.6% - 100%; 30/30) and a specificity of 66.7% (95% CI: 30.0% - 94.1%; 4/6) in pancreatic enhanced CT-positive patients. This means that the application of YiDiXie™-SS reduces the false-positive rate of pancreas-enhanced CT by 66.7% (95% CI: 30.0% - 94.1%; 4/6) with essentially no increase in malignancy leakage. YiDiXie™-HS had a sensitivity of 85.7% (95% CI: 48.7% - 99.3%; 6/7) and a specificity of 84.2% (95% CI: 62.4% -92.5%; 16/19) in enhanced CT-negative patients. This means that YiDiXie ™ -HS reduces the false-negative enhancement CT rate by 84.2% (95% CI: 62.4% -92.5%; 16/19). YiDiXie™-D has a sensitivity of 33.3% (95% CI: 19.2% - 51.2%; 10/30) and a specificity of 100% (95% CI: 61.0% - 100%; 6/6) in patients with positive enhancement CT. This means that YiDiXie™-D reduces the false positive rate of enhanced CT by 100% (95% CI: 61.0% - 100%; 6/6).Conclusion YiDiXie ™ -SS YiDiXie ™ -SS significantly reduces the false-positive rate of pancreatic enhanced CT with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS significantly reduces the false-negative rate of pancreatic enhanced CT. YiDiXie™-D significantly reduces the false-positive rate of pancreatic enhanced CT. The YiDiXie™ test has significant diagnostic value in pancreatic cancer, and is expected to solve the problem of “excessive false-positive rate of enhanced CT” and “excessive false-negative rate of enhanced CT” in pancreatic tumors.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200066840Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.